Why the study?
Do genetic variants in NAD(P)H oxidase and multidrug resistance protein modulate the risk of doxorubicin-induced cardiotoxicity?
Do genetic variants in NAD(P)H oxidase and multidrug resistance protein modulate the risk of doxorubicin-induced cardiotoxicity?
Genetic polymorphisms in NAD(P)H oxidase and multidrug resistance proteins are associated with the risk of developing doxorubicin-induced cardiotoxicity.
Hypothesis-generating for genetic risk stratification in anthracycline therapy; leaves open prospective validation before clinical adoption.
Genetic variants in doxorubicin transport and free radical metabolism may modulate the individual risk to develop ACT.
No takes yet. Share an insight, caveat, or question.
Wojnowski et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: